AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method

Journal of Pharmaceutical Sciences

Volumn 101, Issue 12, 2012, Pages 4490-4500

  Klucker, Marie Françoise ^a   Dalençon, François ^a   Probeck, Patricia ^a   Haensler, Jean ^a  

^a SANOFI PASTEUR   (France)

Author keywords

AF03; Emulsion; Humenza ; PIT; Squalene; Stability; Surfactants; Vaccine adjuvant; Vaccines

Indexed keywords

EID: 84868206480     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23311     Document Type: Article

References (37)

1. Reed SG, Bertholet S, Coler RN, Friede M. 2009. New horizons in adjuvants for vaccine development. Trends Immunol 30:23-32.
2. Leroux-Roels G. 2010. Unmet needs in modern vaccinology. Adjuvants to improve the immune response. Vaccine 28(S3):C25-C36.
3. Simon JK, Edelman R. 2005. Clinical evaluation of adjuvants. In Immunopotentiators in modern vaccines; Schijns V, O′Hagan D, Eds. Amsterdam, The Netherlands: Elsevier B.V., pp 319-342.
4. O′Hagan DT, De Gregorio E. 2009. The path to a successful vaccine adjuvant-'The long and winding road'. Drug Discov Today 14:541-551.
5. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 2009. Vaccine adjuvants: Current challenges and future approaches. J Pharm Sci 98:1278-1316.
6. Garçon N, Leroux-Roels G, Cheng W-F. 2011. Vaccine adjuvants. Perspect Vaccinol 1:89-113.
7. Vogel FR, Caillet C, Kusters IC, Haensler J. 2009. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 8:483-492.
8. O′Hagan DT, Tsai T, Reed S. 2011. Emulsion-based adjuvants for improved influenza vaccines. In Influenza vaccines for the future. Birkhäuser advances in infectious diseases; Del Giudice G, Rappuoli R, Eds. 2nd ed. Basel, Switzerland: Springer Basel AG, pp 327-352.
9. Haensler J. 2011. Oil emulsions as vaccine adjuvants. In Novel immunologic adjuvants; Rappuoli R, De Gregorio E, Eds. London, UK: Future Medicine Ltd., pp 28-40.
10. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. 2008. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198:642-649.
11. O″Hagan DT. 2007. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 6:699-710.
12. Garçon N, Vaughn DW, Didierlaurent AM. 2012. Development and evaluation of AS03, an adjuvant system containing α-tocopherol and squalene in oil-in-water emulsion. Expert Rev Vaccines 11:349-66.
13. Shinoda K, Arai H. 1964. The correlation between phase inversion temperature in emulsion and cloud point in solution of nonionic emulsifier. J Phys Chem 68:3485-3490.
14. Tadros T, Izquierdo P, Esquena J, Solans C. 2004. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 108-109:303-318.
15. Schultze V, D′Agosto V, Wack A, Novicki D, Zorn J, Hennig R. 2008. Safety of MF59 adjuvant. Vaccine 26:3209-3222.
16. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. 2009. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 27:6959-6965.
17. Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P. 2010. Safety review: Squalene and thimerosal in vaccines. Thérapie 65:533-541.
18. Fox CB. 2009. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14:3286-3312.
19. Allison AC. 1999. Squalene and squalane emulsions as adjuvants. Methods 19:87-93.
20. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. 2011. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 29:9563-9572.
21. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. 1995. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In Vaccine design: The subunit and adjuvant approach; Powell MF, Newman MJ, Ed. New York: Plenum Press, pp 277-296.
22. Malcolmson C, Lawrence MJ. 1995. Three-component non-ionic oil-in-water microemulsions using polyoxyethylene ether surfactants. Colloids Surf B Biointerfaces 4:97-109.
23. Tsutsumi H, Kawano J. 1975. Selection of emulsifier by the phase inversion temperature method. Determination of the dispersion types of the emulsion system by the measurement of the physical properties. J Jpn Oil Chem Soc 24:50-55.
24. Förster Th, Schambil F, von Rybinski W. 1992. Production of fine disperse and long term stable oil-in-water emulsions by the phase inversion temperature method. J Dispersion Sci Technol 13:183-193.
25. Orafidiya LO, Oladimeji FA. 2002. Determination of the required HLB values of some essential oils. Int J Pharm 237:241-249.
26. Shinoda K, Kunieda H. 1983. Phase properties of emulsions: PIT and HLB. In Encyclopedia of emulsion technology; Becher P, Ed. Vol. 1. New York: Dekher M, pp 37-367.
27. Förster Th, von Rybinski W, Tesmann H, Wadle A. 1994. Calculation of optimum emulsifier mixtures for phase inversion emulsification. Int J Cosmet Sci 16:84-92.
28. Shinoda K, Saito H. 1969. The stability of O/W type emulsions as functions of temperature and the HLB of emulsifiers: The emulsification by PIT-method. J Colloid Interface Sci 30:258-263.
29. Shinoda K, Takeda H. 1970. The effect of added salts in water on the hydrophile-lipophile balance of nonionic surfactants: The effect of added salts on the phase inversion temperature of emulsions. J Colloid Interface Sci 32:642.
30. 2O-oil-nonionic amphiphile (microemulsions). Angew Chem 24(8):654-668.
31. Kahlweit M, Strey R, Busse G. 1991. Effect of alcohols on the phase behaviour of microemulsions. J Phys Chem 95:5344-5352.
32. Yeo HC, Shibamoto T. 1992. Formation of formaldehyde and malonaldehyde by photooxidation of squalene. Lipids 27:50-53.
33. Huang ZR, Lin YK, Fang JY. 2009. Biological and pharmacological activities of squalene and related compounds: Potential uses in cosmetic dermatology. Molecules 14:540-554.
34. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. 2008. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: Protection against H5N1 challenge without disease enhancement. J Virol 82:2565-2569.
35. Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I. 2010. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 28:3076-3079.
36. Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS. 2011. Report of the 7th Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization; Geneva; 17-18 February 2011. Vaccine 29:7579-7586.
37. Cotte J-F, Sonnery S, Martial F, Dubayle J, Dalençon F, Haensler J, Adam O. 2012. Characterization of surfactants in an oil-in-water emulsion-based vaccine adjuvant using MS and HPLS-MS: Structural analysis and quantification. Int J Pharm Sci 436:233-239.